S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Completed · Phase 2

Conditions studied: Leukemia

In brief

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as gemtuzumab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Gemtuzumab may also stop the growth of promyelocytic leukemia by blocking blood flow to the cancer. Giving gemtuzumab together with combination chemotherapy may be more effective in treating promyelocytic leukemia. PURPOSE: This phase II trial is studying how well giving gemtuzumab together with combination chemotherapy works in treating patients with previously untreated promyelocytic leukemia.

Key facts

Study ID

NCT00551460

Run by

SWOG Cancer Research Network

People needed

78

Starts

2007-11-15

Expected to finish

2018-02-05

Last updated by the study team

2023-01-10

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Sutter Cancer Center — Sacramento, California, United States
• Stanford Cancer Center — Stanford, California, United States
• Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center — Hartford, Connecticut, United States
• Tunnell Cancer Center at Beebe Medical Center — Lewes, Delaware, United States
• CCOP - Christiana Care Health Services — Newark, Delaware, United States
• M.D. Anderson Cancer Center at Orlando — Orlando, Florida, United States
• H. Lee Moffitt Cancer Center and Research Institute at University of South Florida — Tampa, Florida, United States
• Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center — Boise, Idaho, United States
• Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
• Hematology and Oncology Associates — Chicago, Illinois, United States
• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Kellogg Cancer Care Center — Highland Park, Illinois, United States
• Provena St. Mary's Regional Cancer Center - Kankakee — Kankakee, Illinois, United States
• North Shore Oncology and Hematology Associates, Limited - Libertyville — Libertyville, Illinois, United States
• Cardinal Bernardin Cancer Center at Loyola University Medical Center — Maywood, Illinois, United States
• Cancer Care and Hematology Specialists of Chicagoland - Niles — Niles, Illinois, United States
• Swedish-American Regional Cancer Center — Rockford, Illinois, United States
• Hematology Oncology Associates - Skokie — Skokie, Illinois, United States
• Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana, United States
• Siouxland Hematology-Oncology Associates, LLP — Sioux City, Iowa, United States
• Mercy Medical Center - Sioux City — Sioux City, Iowa, United States
• St. Luke's Regional Medical Center — Sioux City, Iowa, United States
• Cancer Center of Kansas, PA - Chanute — Chanute, Kansas, United States
• Cancer Center of Kansas, PA - Dodge City — Dodge City, Kansas, United States
• Sutter Cancer Center at Roseville Medical Center — Roseville, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.